TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03647345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
Study: NCT01880736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study: NCT04261751

Intervention type: OTHER
Intervention: Clinician Questionnaire
Description: Nurses will take the Clinician Questionnaire electronically
Study: NCT02302001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Implant
Study: NCT03086889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion virtual reality (VR)-based rehabilitation
Description: Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.

Intervention type: OTHER
Group type: OTHER
Intervention: traditional rehabilitation training
Description: The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
Study: NCT01417273

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
Study: NCT04074967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib ARRY-614 + nivolumab
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib ARRY-614 + nivolumab+ipilimumab
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Study: NCT02292082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT04074967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Study: NCT01417273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: placebo
Description: 1 cap placebo/day for 12 month
Study: NCT02566655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fucosylated MSC for Osteoporosis
Description: Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.
Study: NCT03750604

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: visceral fat obesity (surface area and function)
Description: WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: visceral fat obesity (surface area and function)
Description: WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein
Study: NCT00005970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibition Therapy
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given orally
Study: NCT02292082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT00005970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT02292082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study: NCT01880736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study: NCT02292082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study: NCT01880736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study: NCT01818869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Multiple doses inhaled IMP via a nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8848
Description: Multiple doses inhaled matching placebo via a nebulizer
Study: NCT01917994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appointment Reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment Reminders
Study: NCT02707666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Neoadjuvant pembrolizumab every 21 days for three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Pemetrexed
Description: Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
Study: NCT01595282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
Study: NCT02574806

Intervention type: PROCEDURE
Intervention: Blood sample and BNP measurement
Description: Blood sample of umbilical artery from umbilical cord immediately after birth.

Intervention type: PROCEDURE
Intervention: Blood sample and BNP measurement
Description: Blood sample of umbilical artery from umbilical cord immediately after birth.
Study: NCT02848560

Intervention type: DRUG
Intervention: Hyperpolarized Xenon
Description: Inhaled contrast for MRI occurring at each of 4 visits.

Intervention type: DRUG
Intervention: Hyperpolarized Xenon
Description: Inhaled contrast for MRI occurring at each of 4 visits.
Study: NCT03886246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection
Study: NCT02292082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT00912964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron tablets
Study: NCT02292082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 MHz. Chiba needle, 22 G / 4 inches
Study: NCT00433966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: 60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Uncoated bare metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: slow rate-release paclitaxel-eluting stent
Study: NCT03139643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Dissonance
Description: After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reflection (Control Condition)
Description: After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
Study: NCT04313400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% w/w AMTX-100 CF-part1
Description: AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical cream manufactured to mimic AMTX-100 CF3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% w/w AMTX-100 CF3-part2
Description: AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
Study: NCT00597623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira®)
Description: syringes for injections under cutaneous dose = 40mg vol = 0.8 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: syringes under cutaneous vol = 8 ml
Study: NCT02924246

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cholera vaccination
Description: Oral cholera vaccination on day 0 and day 14

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raw milk
Description: raw milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pasteurized milk
Description: pasteurized milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UHT milk
Description: UHT milk
Study: NCT03826654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified oil
Description: 35 g fortified sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plain oil
Study: NCT03476694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultra sound guided supraclavicular brachial plexus block
Description: ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultra sound guided supraclavicular brachial plexus block
Description: ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
Study: NCT04094363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand, filtered combustible cigarette
Study: NCT03726918

Intervention type: PROCEDURE
Intervention: Surgery for implantation of a prosthesis
Description: Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes

Intervention type: PROCEDURE
Intervention: Surgery for implantation of a prosthesis
Description: Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
Study: NCT02319616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05% ointment
Description: Blinded, daily application to one arm for a period of fourteen (14) days